Press Releases - Emmaus Medical, Inc.

MYnd Analytics and Emmaus Life Sciences Stockholders Approve Merger and Spin-off TransactionsJuly 10, 2019

The proposed merger and spin-off transactions were approved by their respective stockholders at the special stockholder meetings held yesterday, July 9, 2019

MYnd Analytics and Emmaus Life Sciences Report Progress on Merger and Spin-off TransactionJuly 09, 2019

Merger and Spin-off Transaction on Track to Close by End of July New Spin-Off Record Date Set for July 15, 2019

Emmaus Life Sciences Announces Initiation of its Diverticulosis StudyJuly 08, 2019

Study will evaluate change in number and size of colonic diverticula and assess safety.

Emmaus Life Sciences Announces Hiring Of New Endari® Product ManagerJuly 03, 2019

Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced today the hiring of Michael Schwarz as its new Product Manager for Endari®

Emmaus Life Sciences Announces Protocol for Study of Pharmaceutical-grade L-glutamine for the Treatment of DiabetesJune 24, 2019

Emmaus to use its pharmaceutical-grade L-glutamine ("PGLG") in a clinical study to determine its efficacy in lowering blood sugar in patients with type II diabetes.